Long-term follow-up of patients with hairy cell leukemia in the south of Iran

References

• Benz R, Arn K, Andres M, et al. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv. 2020;4(15):3699–3707.
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood J Am Soc Hematol. 1998;92(6):1918–1926.
   Google Scholar
• Quest GR, Johnston JB. Clinical features and diagnosis of hairy cell leukemia. Best Pract Res Clin Haematol. 2015;28(4):180–192.
   PubMed Web of Science ®Google Scholar
• Troussard X, Maître E, Cornet E. Hairy cell leukemia 2022: update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2022 Feb 1;97(2):226–236.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Aster JC. Clinical features and diagnosis of hairy cell leukemia. In: Waltham, MA: upToDate. 2018.
   Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Golomb HM, Jacobs A, Fefer A, et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin oncol. 1986;4(6):900–905.
   PubMed Web of Science ®Google Scholar
• Quesada JR, Reuben J, Manning JT, et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984;310(1):15–18.
   PubMed Web of Science ®Google Scholar
• Lauria F, Rondelli D, Zinzani P, et al. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia. 1997;11(5):629–632.
   PubMed Web of Science ®Google Scholar
• Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322(16):1117–1121.
   PubMed Web of Science ®Google Scholar
• Hoffman MA, Janson D, Rose E, et al. Treatment of Hairy-Cell Leukemia With Cladribine: response Toxicity, and Long-Term Follow-Up. J Clin oncol. 1997;15(3):1138–1142.
   PubMed Web of Science ®Google Scholar
• Johnston JB, Eisenhauer E, Corbett WE, et al. Efficacy of 2’-Deoxycoformycin in Hairy-Cell Leukemia: a Study of the National Cancer Institute of Canada Clinical Trials Group1. Jnci. 1988;80(10):765–769.
   PubMed Web of Science ®Google Scholar
• Cornet E, Tomowiak C, Tanguy-Schmidt A, et al. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol. 2014;166(3):390–400.
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Catovsky D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015;28(4):217–229.
   PubMed Web of Science ®Google Scholar
• Dearden C, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011 Jun;52(Suppl 2):21–24.
   PubMed Web of Science ®Google Scholar
• Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow‐up of 12.5 years. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2005;104(11):2442–2448.
   Google Scholar
• Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood J Am Soc Hematol. 2009;114(21):4696–4702.
   Google Scholar
• Paillassa J, Cornet E, Noel S, et al. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 2020;10(5):5.
   PubMed Web of Science ®Google Scholar
• Le Guyader-Peyrou S, Defossez G, Dantony E, et al. Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Etude à partir des registres des cancers du réseau Francim. Volume 2: Hémopathies malignes. Saint-Maurice: Santé publique France, 2019.
   Google Scholar
• Inbar M, Herishanu Y, Goldschmidt N, et al. Hairy cell leukemia: retrospective analysis of demographic data and outcome of 203 patients from 12 medical centers in Israel. Anticancer Res. 2018;38(11):6423–6429.
   PubMed Web of Science ®Google Scholar
• Paggano L, Criscuolo M, Broccoli A, et al. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. Blood Cancer J. 2022;12(7):109.
   PubMed Web of Science ®Google Scholar
• Broccoli A, Argnani L, Cross M, et al. A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. Blood Adv. 2022 Jul 26;6(14):4224–4227.
   PubMed Web of Science ®Google Scholar
• Broccoli A, Argnani N, Nanni L, et al. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a 30-year experience. Am J Hematol. 2021 Oct 1;96(10):1204–1210.
   PubMed Web of Science ®Google Scholar
• Else M, Dearden C, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009 Jun;145(6):733–740.
   PubMed Web of Science ®Google Scholar
• Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer: Interdiscip Int J Am Cancer Soc. 2007;110(10):2240–2247.
   Google Scholar
• Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma. 2011;52(sup2):75–78.
   PubMed Web of Science ®Google Scholar
• Ravandi F. Chemo-immunotherapy for hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl2):72–74.71.
   PubMedGoogle Scholar
• Chihara D, Kantarjian H, O’Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174(5):760–766.
   PubMed Web of Science ®Google Scholar
• Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020;38(14):1527–1538.
   PubMed Web of Science ®Google Scholar
• Maitre E, Cornet E, Troussard X. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(12):1413–1422.
   PubMed Web of Science ®Google Scholar
• Jain P, Pemmaraju N, Ravandi F. Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol. 2014;15(2):187–209.
   PubMed Web of Science ®Google Scholar